Carlsmed reports 65% Q3 revenue surge and raises full‑year 2026 guidance
Carlsmed announced third‑quarter 2026 revenue of $21.6 million, a 65% year‑over‑year increase, and lifted its full‑year revenue outlook to $78 million‑$80 million. Gross margin expanded to 77.3% while adjusted EBITDA remained negative at $7.3 million. The company launched its aprevo lumbar bilateral posterior system in October, expects new lumbar reimbursement codes to drive further adoption, and added Jeff Bertolini as COO, Rich Heppenstall as CFO and Dr. Tony Jarc as Chief Product & AI Officer.
Why it matters
The higher revenue and raised guidance suggest stronger demand for Carlsmed’s personalized spine platform, which could improve cash flow and support continued investment in product rollouts. Analysts note the upgraded targets and price‑target increases, indicating potential upside for investors.
Key facts
- 1Q3 2026 revenue was $21.6 million, up 65% YoY. finance.yahoo.com
- 2Gross margin improved to 77.3% in the quarter. finance.yahoo.com
- 3Adjusted EBITDA was a negative $7.3 million. finance.yahoo.com
- 4Cash and investments at quarter‑end totaled $80.3 million. finance.yahoo.com
- 5Full‑year 2026 revenue guidance raised to $78 million‑$80 million. finance.yahoo.com
- 6Jeff Bertolini was promoted to Chief Operating Officer. finance.yahoo.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.